Cytokinetics (CYTK) Convertible Debt (2019 - 2024)
Historic Convertible Debt for Cytokinetics (CYTK) over the last 6 years, with Q3 2024 value amounting to $551.5 million.
- Cytokinetics' Convertible Debt rose 61.06% to $551.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $551.5 million, marking a year-over-year increase of 61.06%. This contributed to the annual value of $549.0 million for FY2023, which is 58.28% up from last year.
- Latest data reveals that Cytokinetics reported Convertible Debt of $551.5 million as of Q3 2024, which was up 61.06% from $550.6 million recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Convertible Debt ranged from a high of $551.5 million in Q3 2024 and a low of $85.5 million during Q1 2020
- For the 5-year period, Cytokinetics' Convertible Debt averaged around $311.9 million, with its median value being $134.7 million (2022).
- As far as peak fluctuations go, Cytokinetics' Convertible Debt soared by 48048.25% in 2022, and later skyrocketed by 57.76% in 2023.
- Quarter analysis of 5 years shows Cytokinetics' Convertible Debt stood at $89.5 million in 2020, then increased by 6.67% to $95.5 million in 2021, then surged by 471.7% to $545.8 million in 2022, then increased by 0.58% to $549.0 million in 2023, then rose by 0.45% to $551.5 million in 2024.
- Its Convertible Debt was $551.5 million in Q3 2024, compared to $550.6 million in Q2 2024 and $549.8 million in Q1 2024.